Takeda Advances Fazirsiran Phase 3 Liver Study, Keeping Rare-Disease Growth Story in Play
Takeda Pharmaceutical Company (TAK) announced an update on their ongoing clinical study.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Takeda (TAK) is running a late-stage study called “A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Fazirsiran in the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease With METAVIR Stage F1 Fibrosis.” The goal is to see if fazirsiran can safely slow or reverse early liver scarring in people with this rare genetic condition, which could open a new high-value niche in liver disease.
The trial tests fazirsiran, an injectable drug designed to lower levels of the abnormal Z-AAT protein that damages the liver. A matched placebo is used as a control, helping show whether any changes in liver health are truly due to the drug rather than to chance or standard care.
The study randomly assigns participants to receive either fazirsiran or placebo, so each person has a fair chance of being in either group. Both patients and doctors are kept blinded to treatment, and the main aim is to assess whether the drug can safely treat disease, using liver biopsies and clinical measures over time.
The trial began after initial submission on 2023-12-01, marking the formal start of Takeda’s phase 3 push in this indication. The latest update was filed on 2026-03-03, showing the study is active and still recruiting, with primary and final completion expected after roughly two years of treatment and follow-up per participant.
For investors, this update underscores Takeda’s effort to build a liver portfolio around genetic and rare disease assets, a space where pricing power can be strong if data are positive. Success could support sentiment around TAK’s longer-term growth story and add pressure on competitors in liver and RNA-silencing drugs, though trial risk remains high until full phase 3 results read out.
The study is ongoing and has been recently updated, with additional details available on the ClinicalTrials portal.
To learn more about TAK’s potential, visit the Takeda Pharmaceutical Company drug pipeline page.
